ライフサイエンスコーパス: transgender

1 proximately 1.4 million persons, identify as transgender.

2 In addition, many studies of transgender adults focus predominantly on younger person

3 For transgender adults, CSHT has been associated with the po

4 miting the generalizability of CSHT in older transgender adults.

5 n consultations for surgical therapy to help transgender and gender-nonconforming individuals.

6 ese effects persisted for 3 months, and both transgender and nontransgender canvassers were effective

7 Prevalence rates of persons identifying as transgender and seeking help with transition have been r

8 h (WPATH) standards of care for transsexual, transgender, and gender non-conforming people (version 7

9 dards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People by the Worl

10 Moreover, transgender astrocytes and microglia made up 1-2% of all

11 there should be a diagnosis of any sort for transgender children below the age of puberty.

12 data, and effective partnerships with local transgender communities to ensure responsiveness of and

13 The World Professional Association for Transgender Health (WPATH) standards of care for transse

14 est evidence supports introducing modules on transgender health early during clinical education of cl

15 Experts in each aspect of transgender health have summarized the content of the gl

16 The World Professional Association for Transgender Health started a global education initiative

17 Consideration of transgender health underscores the need to explicitly co

18 programming for health-care professionals in transgender health, although the best evidence supports

19 le by the World Professional Association for Transgender Health, including mental health, endocrinolo

20 d roles of the mental health professional in transgender health-care decisions, effective models of h

21 rship can be ambiguous (e.g., multiracial or transgender identities) and because different categorica

22 ing aged 21-30 years and reporting female or transgender identity.

23 sitive participants (740 men, 1008 women, 78 transgender individuals and 437 unspecified sex) and 994

24 mic among MSM and transwomen (male-to-female transgender individuals) in Lima, Peru, as a test case.

25 required to provide optimal health care for transgender individuals.

26 essment and treatment of gender dysphoria in transgender individuals.

27 o help guide the treatment and management of transgender individuals.

28 perienced by the lesbian, gay, bisexual, and transgender (LGBT) community and makes a series of recom

29 Lesbian, gay, bisexual, and transgender (LGBT) individuals experience health and hea

30 ion in the study of testosterone therapy for transgender men is a paucity of high-quality data due to

31 with increases in morbidity or mortality in transgender men receiving CSHT.

32 py is a cornerstone of medical treatment for transgender men who choose to undergo it.

33 ansgender women compared with cisgender (non-transgender) men who have sex with men (cis-MSM) in 8 su

34 Similarly, transgender nematodes-animals that appear morphologicall

35 Transgender neurons accounted for 1% of all neurons; the

36 d male sex at birth, 937 (20%) identified as transgender or female, and 3,649 were cis-MSM.

37 imately 24 years, with no difference between transgender participants and cis-MSM.

38 Transgender participants were less likely to report CAI

39 he social and legal conditions in which many transgender people (often called trans people) live, and

40 t currently frames health-care provision for transgender people across much of the world is under scr

41 that frame the provision of health care for transgender people across much of the world.

42 Transgender people are a diverse population affected by

43 y soon abandon its current classification of transgender people as mentally disordered.

44 characterise the population-level health of transgender people globally.

45 We examine research showing that many transgender people live on the margins of society, facin

46 Modern research shows much higher numbers of transgender people than were apparent in earlier clinic-

47 The women, men, and transgender people who sell sex globally have disproport

48 sues and provide better legal protection for transgender people, but this action is by no means unive

49 Some clinical services for transgender people, including gender-affirming surgery,

50 urrounding health risks and resiliencies for transgender people.

51 on, and available surgical interventions for transgender people.

52 Forty percent of transgender persons endorse suicidality, and the rate of

53 hts and media attention, the reality is that transgender persons experience health disparities, and a

54 ual factors contributing to mental health in transgender persons include community attitudes, societa

55 has been made in characterizing the needs of transgender persons wishing to transition to their prefe

56 testing among men who have sex with men and transgender persons within existing and commonly used so

57 earch has identified autistic traits in some transgender persons.

58 re few, and routine surveillance efforts for transgender population health are scarce.

59 scular disease (CVD) and CVD risk factors in transgender populations receiving cross-sex hormone ther

60 their gender identity), existing research in transgender populations suggests that CVD risk factors a

61 although the implementation of services for transgender populations will depend on health system inf

62 in recruitment of representative samples of transgender populations.

63 sence of survey items with which to identify transgender respondents in general surveys often restric

64 ly to address informal sex workers, male and transgender sex workers, and mobile- and internet-based

65 nversion visit, six (18%) of 33 seronegative transgender women (p=0.31), and 58 (52%) of 111 seronega

66 affects men who have sex with men (MSM) and transgender women (TGW).

67 The burden of HIV in transgender women (transwomen) in Brazil remains unknown

68 Transgender women across the world face significant vuln

69 diverse sample of 298 sexually active, young transgender women aged 16 through 29 years (mean age, 23

70 on (OLE) study, men who have sex with men or transgender women aged 18-70 years who were HIV negative

71 Overall HIV prevalence was 25% (235/926) in transgender women and 14% (505/3,594) in cis-MSM.

72 vestigate differences in PrEP outcomes among transgender women and between transgender women and MSM.

73 that HIV burden and stigma differed between transgender women and cis-MSM, indicating a need to addr

74 outcomes among transgender women and between transgender women and MSM.

75 ed recent epidemiological research on HIV in transgender women and show that transgender women sex wo

76 Our findings suggest that transgender women are a very high burden population for

77 youth, including adolescent and young adult transgender women assigned a male sex at birth who ident

78 PrEP group, drug was detected in none of the transgender women at the seroconversion visit, six (18%)

79 he odds ratio for being infected with HIV in transgender women compared with all adults of reproducti

80 nd behavioral drivers of HIV infection among transgender women compared with cisgender (non-transgend

81 Transgender women experience lifelong gender dysphoria d

82 r more characteristics and are classified as transgender women for the purpose of this study.

83 worldwide burden of HIV; however, data among transgender women from the region are sparse.

84 Of the 2499 MSM and transgender women in the iPrEx trial, 1251 were assigned

85 tified a high prevalence of HIV infection in transgender women in the USA and in those who sell sex (

86 Other associated conditions commonly seen in transgender women include increased risks of depression

87 The evidence base for the care of transgender women is limited by the paucity of high-qual

88 Compared with MSM, transgender women more frequently reported transactional

89 Studies of PrEP use in transgender women populations should be designed and tai

90 and comorbid psychiatric disorders in young transgender women remain scarce.

91 ble participants were HIV-uninfected men and transgender women reporting condomless anal intercourse

92 The overall PAF for MSM and transgender women reporting receptive anal intercourse w

93 In 3869 transgender women sampled in five high-income countries,

94 In 7197 transgender women sampled in ten low-income and middle-i

95 NNTs were lowest for MSM and transgender women self-reporting receptive anal intercou

96 ch on HIV in transgender women and show that transgender women sex workers (TSW) face unique structur

97 udies that assessed HIV infection burdens in transgender women that were published between Jan 1, 200

98 idence of HPV among vaccine-eligible MSM and transgender women to monitor vaccine impact.

99 tive anal sex, the odds of HIV infection for transgender women were 2.2 times greater than the odds f

100 Compared to cis-MSM participants, transgender women were more likely to experience family

101 Transgender women were more likely to report condomless

102 e effective in preventing HIV acquisition in transgender women when taken, but there seem to be barri

103 Worldwide, transgender women who engage in sex work have a dispropo

104 domly assigned 2499 HIV-seronegative men and transgender women who have sex with men (MSM) to receive

105 In our cohort study, men and transgender women who have sex with men previously enrol

106 ndomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a com

107 t 21 sites, we randomly assigned 2504 men or transgender women who have sex with men to receive the D

108 oxil fumarate among HIV-seronegative men and transgender women who have sex with men: HIV infection w

109 population level if targeted toward MSM and transgender women who report receptive anal intercourse

110 modelling was used to compare HIV burdens in transgender women with that in adults in the countries f

111 s known about the burden of HIV infection in transgender women worldwide.

112 better assess the relative HIV burden in all transgender women worldwide.

113 lence was 19.1% (95% CI 17.4-20.7) in 11 066 transgender women worldwide.

114 Of the 298 transgender women, 41.5% of participants had 1 or more m

115 For transgender women, CSHT has known thromboembolic risk, a

116 acebo in men who have sex with men (MSM) and transgender women, followed by an open-label extension.

117 Among transgender women, there were 11 HIV infections in the P

118 e sex at birth who identify as girls, women, transgender women, transfemale, male-to-female, or anoth

119 to behavioural indicators of HIV risk among transgender women, whereas MSM at highest risk were more

120 hormone-sensitive cancer seems to be low in transgender women, with no increased risk of breast canc

121 acquisition in men who have sex with men and transgender women.

122 in 2499 men who have sex with men (MSM) and transgender women.

123 sks of pre-exposure prophylaxis with MSM and transgender women.

124 and severity of the HIV disease burden among transgender women.

125 is in Peruvian men who have sex with men and transgender women.

126 in this community-recruited sample of young transgender women.

127 eronegative men who have sex with men and in transgender women.

128 EP efficacy, effectiveness, and adherence in transgender women.

129 sition of HIV in groups at high risk such as transgender women.

130 Transgender youth, including adolescent and young adult